Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Frontiers in Immunology|March 31, 2022
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck CancerJames H A Clubb, Tatiana V Kudling, Camilla Heiniö, et al.
Oncoimmunology|September 14, 2020
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibitionVictor Cervera-Carrascon, Dafne C A Quixabeira, Joao Manuel Santos, et al.
Frontiers in Immunology|July 21, 2023
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippageSanteri Pakola, Dafne C A Quixabeira, Tatiana V Kudling, et al.
Frontiers in Immunology|August 9, 2021
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1Victor Cervera-Carrascon, Dafne C A Quixabeira, Joao M Santos, et al.
Molecular Therapy Oncolytics|January 26, 2023
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumorsSaru Basnet, Joao M Santos, Dafne C A Quixabeira, et al.
Molecular Therapy Oncolytics|April 24, 2020
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid TumorsVictor Cervera-Carrascon, Dafne C A Quixabeira, Riikka Havunen, et al.
Oncoimmunology|August 7, 2023
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancerTatiana V Kudling, James H A Clubb, Santeri Pakola, et al.
Oncoimmunology|July 18, 2022
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regressionTatiana V Kudling, James H A Clubb, Dafne C A Quixabeira, et al.
Frontiers in Immunology|February 23, 2023
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive settingJames H A Clubb, Tatiana V Kudling, Mykhailo Girych, et al.
Pageof 3